ClinicalTrials.gg
RecruitingNCT06501599Updated Jul 22, 2024

AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes

An observational study in Pneumonia, Viral and COVID-19 Pneumonia, sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
563
Ages
18 Years and older
Sex
All
01

Study summary

The AI-based system designed to process chest computed tomography (CT) aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4).

The retrospective study aims to demonstrate the clinical validation of the AI-based system. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined to provide evidence about the clinical efficacy of the AI-based system.

The hypothesis is that the measures of clinical validation of the AI-based system differ by no more than 8% from those declared by the manufacturer.

Read the detailed description

The AI-based system designed to process chest CT aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4).

This retrospective clinical study will provide the clinical validation of the AI-based system to analyze chest CT images and identify pathological patterns associated with interstitial changes in pneumonia. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined and compared with values declared by the manufacturer to provide evidence about the clinical efficacy of the AI-based system.

The first stage of clinical validation is the collection of a verified labeled dataset. For this purpose, the dataset is collected, labeled, and verified by a research group. The verified dataset should include chest CT images without infiltrative and interstitial lung changes characteristic of viral pneumonia, including COVID-19-associated (CT-0) and chest CT images of all degrees of lung involvement CT-1 (≤25%), CT-2 (25-50%), CT-3 (50-75%), CT-4 (≥75%) [1]. Forming the verified dataset will allow reliable conclusions to be drawn upon completion of the clinical validation. The verified dataset must include a sufficient volume of chest CT images. The verified dataset must be de-identified to ensure the safety of patient personal data.

The second stage of the clinical validation is assessing AI-based system performance by experts. For that purpose, the AI software is analyzed to identify radiological signs of viral pneumonia. Then an examination is made of the correctness of the quantitative assessment of lung damage associated with interstitial changes in pneumonia. The evaluation of both the ability to correctly identify signs of lung damage and to quantify the identified changes is carried out on the same verified dataset.

The third stage of clinical validation is the calculation of clinical efficacy metrics (accuracy, sensitivity, specificity, area under the ROC-curve (AUROC) of the AI-based system by testing it on a verified data set. Testing of the hypothesis to verify the main diagnostic characteristics (sensitivity and specificity) declared by the manufacturer is planned by constructing a two-sided 95% confidence interval (CI), which should not differ by more than 8% from the declared values of 95% and 97%, respectively. Those. the lower limit of the 95% CI for sensitivity should not cross the 87% threshold, and the lower limit of the 95% CI for specificity should not cross the 89% threshold.

All stages of the clinical trial must be under the control of the Principal Investigator.

Randomization of images is not provided in this clinical study, because All CT images will be assessed by the research group and AI software. Also, this design does not involve blinding or masking of the research team. The evaluation of CT images by experts and the software is carried out independently, i.e. the results of each party's assessment are not known to the other party in advance.

02

Conditions studied

  • Pneumonia, Viral
  • COVID-19 Pneumonia

Browse trials for

Keywords

  • Artificial Intelligence
  • Machine Learning
  • Computed tomography
  • Chest CT
03

In context

Pneumonia, Viral

156 studies on the registry are indexed under Pneumonia, Viral; 12 are open to participants now.

This study's planned enrollment of 563 is above the median of 233 across 55 observational studies indexed under Pneumonia, Viral.

Browse Pneumonia, Viral studies →

Lead sponsor

Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults (patients over 18 years of age) who were referred for a chest CT study by a physician in case of suspicion or monitoring the effectiveness of treatment of diseases manifested by changes in the pulmonary parenchyma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. General

    1. Patients over 18 years old;
    2. Patients who underwent CT without contrast enhancement;
    3. Patients who underwent a CT scan according to a standardized scanning protocol: 120 kilovolts, slice thickness max. 2 mm, rigid "lung" filter (kernel) reconstruction;
    4. Patients whose studies should be of acceptable quality, performed with breath-holding, without technical artifacts, and respiratory and motor artifacts;
    5. Patients whose studies must contain DICOM tags responsible for the orientation and position of the patient in the images during the study, as well as DICOM tags responsible for the size of the scans and image parameters;
    6. Patients in whom the localization of changes is predominantly bilateral, in the basal and subpleural parts of the lungs, may be located peribronchial;
  2. For group Normal

    a. Patients who do not contain COVID-19-related CT patterns;

  3. For groups Mild, Moderate, Severe, and Critical

    1. Patients who contain COVID-19-related CT pattern: ground glass opacities (mild, moderate, and higher intensity);
    2. Patients who contain COVID-19-related CT pattern: pulmonary consolidation;
    3. Patients who contain COVID-19-related CT pattern: cobblestone infiltration of the lung parenchyma;
    4. Patients who contain COVID-19-related CT pattern: hydrothorax;
    5. Patients who contain a combination of one or more patterns.

Exclusion criteria

Exclusion Criteria:

  • Patients whose studies contain images with unreported CT patterns;
  • Patients whose examinations do not conform to DICOM format;
  • Patients whose examinations do not contain imaging of the lung region
  • Patients whose examinations contain technical artifacts caused by malfunctions or features of CT scanners;
  • Patients whose examinations contain improper patient positioning;
  • Patients whose examinations contain studies with deleted DICOM tags responsible for scan size and image parameters;
  • Patients whose examinations contain metal artifacts on the patient's body and clothing;
  • Patients whose examinations contain the presence of other pathologic changes of lungs in patients - neoplastic, tuberculosis process, bacterial pneumonia, etc.;
  • Patients under 18 years old.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
563 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal

    CT-0. Not consistent with pneumonia (including COVID-19). \[1,2\] Enrollment number: 95

    Diagnostic Test: Medical software (AI-based system)

  • Mild

    СT-1. Ground glass opacities. Pulmonary parenchymal involvement =\<25% OR absence CT signs in typical clinical manifestations and relevant epidemiological history \[1,2\]. Enrollment number: 117

    Diagnostic Test: Medical software (AI-based system)

  • Moderate

    CT-2. Ground glass opacities. Pulmonary parenchymal involvement 25-50% \[1,2\]. Enrollment number: 117

    Diagnostic Test: Medical software (AI-based system)

  • Severe

    CT-3. Ground glass opacities. Pulmonary consolidation. Pulmonary parenchymal involvement 50-75%. Lung involvement increased in 24-48 hours by 50% in respiratory impairment per follow-up studies \[1,2\]. Enrollment number: 117

    Diagnostic Test: Medical software (AI-based system)

  • Critical

    CT-4. Diffuse ground glass opacities with consolidations and reticular changes. Hydrothorax (bilateral, more on the left). Pulmonary parenchymal involvement \>=75% \[1,2\]. Enrollment number: 117

    Diagnostic Test: Medical software (AI-based system)

Interventions

  • Diagnostic testMedical software (AI-based system)

    Retrospective analysis of chest CT images with medical software (AI-based system)

06

What researchers measure

Primary outcomes

  1. Accuracy

    The ability of an AI-based system to produce the correct result relative to the total number of trials

    Time frame: Upon completion, up to 1 year

  2. Sensitivity

    Effectiveness of the AI-based system to correctly identifies patients with the suspected viral pneumonia related lung changes

    Time frame: Upon completion, up to 1 year

  3. Specificity

    Effectiveness of the AI-based system to correctly identifies across a range of available measurements patients that do not have the suspected viral pneumonia related lung changes

    Time frame: Upon completion, up to 1 year

  4. AUC ROC

    The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI-based system in prediction of suspected viral pneumonia related lung changes

    Time frame: Upon completion, up to 1 year

Secondary outcomes

  1. Approximate volume of affected lung tissue

    Approximate volume of affected lung tissue - quantitative characteristics of lung damage volume in percent (%): separately for left lung, right lung and total percentage of damage

    Time frame: Time Frame: Upon completion, up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
    Moscow, 127051, Russian Federation
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 15, 2024
StartActual
Jun 3, 2024
Primary completionEst.
Jun 3, 2025
CompletionEst.
Dec 3, 2025
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501599
Lead sponsor
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Collaborators
Sciberia Co. Ltd
Responsible party
Anton V. Vladzymyrskyy (Chief Research Officer, Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department) — Principal investigator
First posted
Jul 15, 2024
Start date
Jun 3, 2024
Primary completion
Jun 3, 2025 (estimated)
Completion
Dec 3, 2025 (estimated)
Last update
Jul 22, 2024

Study contacts

Victoria Zinchenko
Contact
ZinchenkoVV1@zdrav.mos.ru
+7 (495) 276-04-36
Anton Vladzymyrskyy
Contact
VladzimirskijAV@zdrav.mos.ru

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion